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The time course of accumulation of herpes simplex virus immediate-early (IE) mRNA and the requirement
for infected cell protein synthesis for mRNA transcription and accumulation were compared. Measurements of
transcription in nuclear run-on assays, accumulation of cytoplasmic mRNA by Northern (RNA) blot
hybridization, and rates of infected cell protein synthesis by pulse-labeling did not indicate differences among
the five IE genes, consistent with previous studies. However, as a result of varying the amount of de novo
protein synthesis after infection, at least three patterns of maximal expression of the IE genes were revealed.
Addition of the protein synthesis inhibitor anisomycin to cells coincident with infection resulted in maximal
rates of transcription and accumulation of functional ICPO mRNA, while 0.5 h of infected cell protein synthesis
prior to addition of the drug was required for maximal expression of ICP22/47 and ICP27 mRNAs. Maximal
expression of ICP4 mRNA occurred only when 1 h of de novo protein synthesis occurred prior to the addition
of the drug. These results are discussed in the context of alternative mechanisms for regulating IE gene
expression.
Expression of the herpes simplex virus (HSV) genome is
temporally regulated at the transcriptional level. Early stud-
ies defined the time of appearance and thus the kinetic
classification of infected cell proteins on the basis of require-
ments for either de novo protein or DNA synthesis (29, 30).
Analysis of infected cell transcription patterns revealed that
no protein synthesis was required for the accumulation of
functional immediate-early (IE) mRNA, while 2 to 3 h of
infected cell protein synthesis was required for accumulation
of delayed-early (DE) mRNAs. The late (L) genes could be
subclassified into those (gamma-1) requiring 3 to 5 h of
protein synthesis and others (gamma-2) requiring in addition
the onset of viral DNA replication (9, 27, 31, 64, 66). During
productive infection, viral gene expression is initiated by
interaction of a structural component of the virion, variously
termed VP16, ICP25, Vmw65, or (x-TIF (4, 7, 43), with the
cellular transcription factor Oct-1 (23, 34, 38, 46, 47, 55, 65)
and at least one additional cellular protein (23, 32, 35, 68)
resulting in interaction with cognate binding sites (the TAA
TGARAT sequence), present one or more times in IE
promoters (5, 18, 33, 40, 41). This regulatory network,
however, is dispensable at least for growth in tissue culture
since viral DNA is infectious and a mutant carrying a 12-bp
insertion in the structural gene for VP16 is viable (1). Though
efficiency of replication of the mutant is severely impaired at
low multiplicity of infection (>10 particles per cell [1]), it is
capable of establishing and maintaining a latent infection and
efficiently reactivating from a mouse eye latency model (63).
The products of two IE genes play critical roles in the
subsequent expression of DE and L genes. A large number
of mutational analyses of infected cell protein 4 (ICP4) as
well as cotransfection assays have demonstrated that this
gene product is essential for DE and L gene transcription
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and is required in a functional form throughout the replica-
tion cycle (11, 24, 37, 54, 66). Similarly, ICP27 is a multi-
functional protein which stimulates expression of gamma-1
genes and is essential for gamma-2 gene expression (57, 60,
62).
Genetic studies have indicated a role for a third IE protein,
ICP0 (2, 30, 51, 52), in efficient reactivation from latency (8,
26, 36, 59, 71). In addition, viral DNA from ICP0 mutant
viruses is less efficient at initiating foci of infection than is
wild-type DNA when transfected into permissive cells (6).
Finally, ICP0 has been shown to transactivate viral IE, DE,
and L promoters alone or in combination with other HSV
transactivating proteins in transfected cells (13, 14, 19, 20,
45, 48, 49, 56, 62). Taken together, these findings suggest an
important role for ICP0 in very early events of viral gene
expression, particularly in the absence of VP16. At least one
study has reported the absence of Oct-1 (but not other
members of the POU domain regulatory protein family) from
adult mammalian sensory ganglia or spinal cord (28). On the
assumption that temporally regulated viral gene expression
occurs during reactivation from latency, it could be argued
that an alternative pathway, underlying and independent of
VP16-Oct-1 interactions, exists for activating IE gene
expression.
We initiated comparative studies of IE mRNA metabolism
in order to gather information on rates of transcription,
accumulation of functional mRNA, and requirements for
maximal expression. Our results support a model for effi-
cient expression of IE genes which relies, at least in part, on
the expression of one or more IE proteins.
MATERIALS AND METHODS
Cells and virus. Vero cells were grown in Dulbecco's
modified Eagle medium-H (DMEM-H) supplemented with
5% bovine calf serum. HSV-1 strain F was used throughout
this study and propagated as described previously (27). All
infections were performed at a multiplicity of infection of 10
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for 1 h. Times postinfection (p.i.) were calculated from the
time of addition of the inoculum.
Analysis of protein synthesis. Replicate 35-mm cultures of
Vero cells were infected and then treated with 25 F.M
anisomycin where indicated in the figure legends. Experi-
ence with emetine and cycloheximide at the outset of these
studies suggested that these drugs were not ideally suited,
since the former had toxic effects on cells when present for
prolonged periods (5 to 8 h), and the latter did not rapidly
reverse under our conditions of drug treatment. At 7 h p.i.,
DMEM-H containing drug was removed, and monolayers
were washed once with drug-free medium and overlaid with
DMEM-H containing actinomycin D (5 pug/ml). After 30 min,
the medium was removed, and the monolayers were washed
twice with methionine-free medium and labeled for 30 min
with methionine-free medium supplemented with 5% dia-
lyzed fetal calf serum and 30 ,uCi of [35S]methionine per ml.
Lysates were prepared by washing monolayers with phos-
phate-buffered saline (PBS) and scraping cells into a buffer
consisting of 5 mM Tris (pH 6.8), 1.4 M 2-mercaptoethanol,
2% sodium dodecyl sulfate (SDS), 5% glycerol, and 0.0001%
bromophenol blue. Protein samples were boiled for 3 min
prior to storage at -70°C. Aliquots of protein lysates were
electrophoresed on 9% acrylamide SDS-polyacrylamide gels
cross-linked with N,N-diallyl tartardiamide as described
previously (27, 61). Autoradiographs of the resulting gels
were prepared by fluorography.
Analysis of steady-state RNA levels. Replicate 100-mm
cultures of Vero cells were infected and harvested at indi-
cated times between 0.5 and 14 h p.i. or infected in the
presence of drugs as indicated and harvested at 8 h p.i.
Cytoplasmic RNA samples were prepared, and 5-jg aliquots
were fractionated on formaldehyde agarose gels and then
transferred to nitrocellulose membranes as described previ-
ously (27). Double-stranded DNA probes (0.5 jig of plasmid
insert) were labeled by nick translation and hybridized to
replicate Northern (RNA) blots as previously described (27,
61). The following mRNA-specific hybridization probes
were used: for ICP4, a BamHI (0.844 to 0.856/0.964 to 0.976
map units [m.u.]) 1.8-kb fragment (Bam Y [53]); for ICPO, a
BamHI-PstI (0.022 to 0.052 m.u.) 4.5-kb fragment from
pRB111 (53); for ICP22, a PvuII-BstEII (0.869 to 0.874 m.u.)
0.75-kb fragment from pSG25 (25); for ICP27, a BamHI-SalI
(0.741 to 0.748 m.u.) 1.05-kb fragment from pSG28 (25); and
for ICP47, a BamHI-BstEII (0.952 to 0.955 m.u.) 0.45-kb
fragment from pSG25 (25, 58). In the interest of space and
convenience of presentation, only those portions of the
autoradiographs containing signal are presented (Fig. 1 and
3).
Analysis of transcription rates. (i) Isolation of nuclei. Nuclei
were isolated by the method of Marzluff (44). Briefly,
100-mm cultures of infected cells were washed with PBS,
resuspended in lysis buffer [0.32 M sucrose, 3 mM CaCl2, 2
mM Mg(CH3COO)2, 10 mM Tris-HCl (pH 8), 1 mM dithio-
threitol (DTT), 0.1% Triton X-100] at 10 x 106 to 50 x 106
cells per ml and disrupted by Dounce homogenization. The
lysate was diluted with 0.5 volume of suspension buffer [2.0
M sucrose, 5 mM Mg(CH3COO)2, 10 mM Tris-HCl (pH 8), 1
mM DTT], layered over a 2-ml cushion of suspension buffer,
and centrifuged for 45 min at 25,000 x g at 4°C. The nuclear
pellet was resuspended in storage buffer [25% glycerol, 5
mM Mg(CH3COO)2, 50 mM Tris-HCl (pH 8), 5 mM DTT]
and stored in liquid N2 for up to 1 month prior to use.
(ii) Run-on transcription. Thawed nuclei were diluted with
a reaction mix to give final concentrations of 10 mM Tris-
HCl (pH 8), 5 mM MgCl2, 0.3 M KCl, 2 mM ATP, CTP, and
UTP, 5 mM DTT, and 100 ,u Ci of [at-32P]GTP (800 Ci/mmol,
10 mCi/ml). Reaction mixes were incubated for 30 min at
25°C. Control reactions for RNA polymerase II were per-
formed in the presence of 100 ,ug of a-amanitin per ml; under
these conditions, no hybridizable counts per minute were
detectable (data not shown). Reactions were stopped by
addition of 1.5 volumes ofHSB (0.5 M NaCl2, 50 mM MgCl2,
2 mM CaCl2, 10 mM Tris-HCl [pH 7.4]) containing 50 ,ug of
RNAse-free DNAse I per ml and further incubation at 30°C
for 5 min.
(iii) Preparation of RNA, hybridization conditions, and
quantitation. Nuclei were digested by the addition of 0.2
volume of 5% SDS-0.5 M Tris-HCl (pH 7.4)-0.125 M EDTA
and proteinase K (200 ,ug/ml) and incubation at 42°C for 30
min. RNA was extracted twice with phenol-chloroform-
isoamyl alcohol (25:24:1) and precipitated on ice for 30 min
in 1 volume of 20% trichloroacetic acid and 100 pug of tRNA
per ml. The RNA was pelleted, washed four times with 5%
trichloroacetic acid resuspended in 200 [L of [N-tris(hydroxy-
methyl)methyl-2-aminoethanesulfonic acid] (TES) buffer (10
mM TES [pH 7.4], 10 mM EDTA, 0.2% SDS) and precip-
itated by addition of 2 volumes of 95% ethanol. RNA was
pelleted, resuspended in 1 ml of TES buffer, and, following
limited hydrolysis of the RNA in 1 N NaOH, diluted to 5 ml
by addition of TES buffer-0.6 M NaCl. Labeled run-on RNA
was hybridized for 36 h at 65°C to single-stranded phage M13
probes immobilized on nitrocellulose filters, specific for
ICP4, ICPO, ICP22, ICP27, ICP8, ICP5, and gC mRNAs.
DNA inserts complementary to mRNA encoding ICP4,
ICP8, ICP5, and gC (24) and ICP22 and ICP27 (37) have been
previously described. The DNA insert complementary to
ICPO mRNA is a 658-bp XmaI-SalI fragment near the 3' end
of the gene (from W. Sacks and P. Schaffer). Prior to use in
run-on transcription analyses, the specificity of each clone
was verified by Northern blot hybridization against RNA
preparations isolated from cells infected in the presence of
anisomycin or in the absence of drug at various times p.i.
Filters were washed twice for 1 h in 2x SSC (0.3 M NaCl,
0.03 M sodium citrate) at 22°C, once for 30 min at 37°C in 2x
SSC containing 10 jig of RNase A per ml, and once for 1 h in
2x SSC at 370C. Filters were air dried, and hybridization
was quantitated with an AMBIS radioanalytic beta scanner.
RESULTS
Kinetics of appearance and metabolic requirements for
individual IE gene expression. We previously reported exper-
iments which defined in Vero cells the kinetics of appearance
of representative IE (ICP4 and ICPO), DE (thymidine ki-
nase), and L (ICP5) mRNAs and the metabolic requirements
for their accumulation; in addition, we presented a time
course of appearance of infected cell proteins in which the
corresponding protein products could be identified (27).
Figure 1 presents a comprehensive Northern blot analysis of
all five IE genes, based on identical RNA samples purified
from replicate Vero cell cultures. At the indicated times,
cytoplasmic RNA was isolated and fractionated by formal-
dehyde gel electrophoresis, transferred to nitrocellulose, and
hybridized with labeled DNA probes as described in Mate-
rials and Methods. Where indicated, cells were treated with
25 puM anisomycin or 2.0 mM canavanine in arginine-free
medium or 10 mM phosphonoacetate (PAA). In this analy-
sis, all of the IE mRNAs accumulated as early as 1 h p.i.,
peaked in accumulation at 3 to 5 h p.i., and thereafter
declined in relative abundance (Fig. 1A). The additional
transcript detected with the ICP47 probe and displaying late
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FIG. 1. Kinetics and metabolic requirements for accumulation of
IE mRNAs. Northern blot analysis of cytoplasmic RNA isolated
from infected cells at indicated times (hours) p.i. (A) or under
various conditions of infection (B) are presented. IE mRNA-specific
probes and conditions of drug treatment are described in Materials
and Methods. M, mock-infected cells; CAN, canavanine; ANI,
anisomycin; 3H, 3-h-p.i. no-drug control; 8H, 8-h-p.i. no-drug
control. Mock and drug-treated RNA samples were from cells
harvested at 8 h p.i. The ICP designations at the left refer to the IE
protein-coding potential of the corresponding mRNAs; an alterna-
tive nomenclature refers to these mRNAs as lEl, IE3, IE4, IE5, and
IE2, respectively. The additional transcript detected by the ICP47
probe beginning at 5 h p.i. (A) and in the 8-h sample (B, lane 8H) is
the 1.5-kb L mRNA of the US11 gene (57).
gene kinetics is US11 mRNA (57). Importantly, the absence
of requirements for de novo protein synthesis (anisomycin)
and viral DNA replication (PAA) for at least minimal accu-
mulation were shared by all IE species (Fig. SB).
Earlier reports demonstrated that the normal transition
from IE to DE and L gene expression required functional IE
proteins, since treatment of cells from the onset of infection
with the arginine analog canavanine resulted in IE gene
expression but no DE or L gene expression (30, 51). Treat-
ment with the arginine analog canavanine (Fig. 1B) demon-
strated that normal metabolism of IE mRNA requires the
presence of functional infected cell proteins. While levels of
ICP22, ICP27, and ICP47 mRNAs were reduced to approx-
imately 20% of control (lane 3H) levels and to approximately
10% of the levels attained in the absence of protein synthesis
(lane ANI), they were higher than the levels normally seen in
control cells infected for an equivalent time in the absence of
drug (lane 8H). Similar results were obtained for ICP4 and
ICPO mRNA levels when the effects of canavanine and
anisomycin were compared, though canavanine-treated sam-
ples and the 8-h control levels were comparable. The latter
result probably reflects the persistence of ICP4 and ICPO
mRNAs at late times p.i. compared with ICP22, ICP27, and
ICP47 (Fig. 1A and reference 27). For all of the IE mRNAs,
the difference between the levels of mRNA obtained in the
absence of protein synthesis (Fig. 1B, lane ANI) and the
presence of defective proteins (lane CAN) is striking. The
overaccumulation of IE mRNAs in the presence of protein
synthesis inhibitors as well as genetic analyses (11, 48, 50)
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FIG. 2. Effect of the time of anisomycin addition on the subse-
quent pattern of infected cell protein synthesis after drug reversal.
Samples of [35S]methionine-labeled proteins from infected cells
initially treated with anisomycin between 0 and 2 h p.i., as indicated
below the lanes, and labeled from 7.5 to 8 h p.i. were separated by
SDS-PAGE as described in Materials and Methods. Lane 8 contains
control 8-h-infected cell proteins. The mobilities of various infected
cell proteins (alpha [IE] 4, 0, 22, and 27, beta [DE] 6 and 8, and
gamma [L] 5) are indicated. Other numbers refer to molecular sizes
(in kilodaltons) of marker proteins (lane M).
of IB gene expression (but see reference 17), though it is
unclear how repression is mediated for each of the individual
IB genes. Reduced levels of IE mRNA in the presence of
canavanine suggest that one or more infected cell proteins
play a positive regulatory role in mRNA synthesis or
accumulation (see Discussion).
We previously noted an altered mobility of ICPO mRNA
isolated from canavanine-treated cells (27) and have ob-
served similar results with ICP22 and ICP47 mRNAs.
Whether this is related to the spliced structure of these three
mRNAs is unknown. Of interest, however, is the finding that
both species of mRNA in the time course show a similar
decrease in relative mobility by 8 h p.i. (compare Fig. 1A,
lane 8H, with Fig. iB, lanes CAN and 8H). Finally, the
increased accumulation of mRNA in the presence of PAA
relative to the 8-h untreated control is consistent with the
observation that failure to express DE and L proteins leads
to defective shutoff of gene expression (10, 24, 30, 54).
Effects of de novo protein synthesis on IE gene expression.
(i) SDS-PAGE and Northern blot analyses. The first indication
that an additional level of regulation might exist in the
metabolism of mRNA occurred when we determined that
infected cell protein synthesis was required to achieve
maximal expression of mRNAs. The protein synthesis
inhibitor anisomycin was added to replicate infected cultures
at progressively later times between 0 and 2 h p.i. The drug
was removed at 8 h p.i,, and proteins pulse-labeled with
[15S]methionine and analyzed by SDS-polyacrylamide gel
electrophoresis (PAGE) as described in Materials and Meth-
ods. Thus, the pattern of proteins detected should reflect the
ability of infected cells to accumulate the corresponding
mRNAs in the presence of 0 h, 1 h, h 20 min, 1 h 40 min,
2 h, and 8 h of de novo infected cell protein synthesis.
Results of the analysis (Fig. 2) revealed the following: (i) the
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FIG. 3. Effect of the time of anisomycin addition on the accu-
mulation of IE mRNAs. Cytoplasmic RNA from infected cells
initially treated with anisomycin between 0 and 2 h p.i., as indicated
below the panels, was purified from cells at 8 h p.i. and analyzed by
Northern blot hybridization as described in Materials and Methods.
(A) Autoradiographic results of Northern blots of IE mRNAs.
Designations at the left refer to the protein-coding potential of the
mRNAs as described in the legend to Fig. 1. (B and C) Relative
amounts of individual IE mRNAs determined by laser densitometry
of autoradiographs as described in Materials and Methods. To
ensure linearity of the response, X-ray films of different lengths of
exposure of each Northern blot (not necessarily those shown in
panel A) were scanned. (B) 0, IE ICP4; 0, IE ICPO. (C) 0, lE
ICP27; *, IE ICP22; O, IE ICP47.
which were treated with anisomycin initially at the time of
infection (0 h p.i.), and (ii) rates of ICP4, ICP22, and ICP27
were maximal when 1 h 20 min of infected cell protein
synthesis was allowed prior to the anisomycin block. Two
additional observations, aside from differential effects of
anisomycin on maximal rates of IE protein synthesis, can be
made: (i) 1 h 20 min of infection was required for the
synthesis, maturation, and localization of positive regulatory
factors controlling levels of DE and L gene expression (e.g.,
ICP8 and ICP5), and (ii) an additional 20 min (1 h 40 min) of
infection was required for synthesis of negative regulatory
factors controlling levels of IE expression (see also Fig. 3A).
Northern blot analysis (Fig. 3) revealed a pattern of
dependence on infected cell protein synthesis for the maxi-
mal accumulation of IE mRNAs, consistent with the previ-
ous data on rates of protein synthesis. Anisomycin was
added at the indicated times, and cells were harvested and
RNA was extracted at 8 h p.i. The autoradiographic results
of the hybridizations (Fig. 3A) indicate that the highest
accumulation of ICPO mRNA occurred in the complete
absence of infected cell protein synthesis, while periods of 1
h and 1 h 20 min were required for maximal accumulation of
ICP4, ICP22, and ICP47 mRNAs and ICP27 mRNA, respec-
tively. Figures 3B and C summarize densitometric analysis
of the hybridization results. Steady-state levels of ICP0
mRNA declined continuously through the course of the
experiment, while levels of ICP4 mRNA initially increased
to a maximum when drug addition was delayed to 1 h p.i.
(Fig. 3B). Levels of ICP22, ICP27, and ICP47 increased
through 1 h to 1 h 20 min before declining (Fig. 3C). It is clear
that by 2 h p.i., DE or gamma-1 gene products had accumu-
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FIG. 4. Effect of the time of anisomycin addition on the tran-
scription rates of IE, DE, and L mRNAs. Run-on transcripts were
purified from nuclei of infected cells initially treated with anisomy-
cin between 0 and 3 h p.i., as indicated below the panels, and
hybridized to single-stranded mRNA-specific DNA probes, and the
transcription rates of the resulting hybrids were quantitated, all as
described in Materials and Methods. Results are presented as
percentage of maximum counts per minute hybridized. (A) 0, IE
ICPO, maximum cpm = 1,412; 0, IE ICP4, maximum cpm = 2,165.
(B) 0, IE ICP22, maximum cpm = 1,510; *, IE ICP27, maximum
cpm = 1,174. (C) 0, DE ICP8, maximum cpm = 3,237. (D) 0, L
ICP5, maximum cpm = 1,342; 0, L gC, maximum cpm = 1,655.
decline in levels of IE mRNAs normally seen after 5 h of
infection (compare Fig. 3A with Fig. 1A).
(ii) Run-on nuclear transcription analysis. To determine
whether the apparent requirement for infected cell protein
synthesis was at the transcriptional or posttranscriptional
level, run-on assays were performed by using nuclei from
cells treated with anisomycin for increasing times between 0
and 3 h p.i. All cells were harvested and nuclei were
prepared at 5 h p.i. as described in Materials and Methods.
If the protein synthesis requirement were at the level of
transcription, we would expect rates of RNA synthesis to
mirror results from the previous protein synthesis and
mRNA accumulation analyses (Fig. 2 and 3). Alternatively,
if the requirement were posttranscriptional, then rates of IE
transcription should be similar and the previous results
would likely reflect differential mRNA stability or transla-
tional efficiency. Figure 4 summarizes results of beta emis-
sion densitometry scanning of slot blot hybridization exper-
iments. Panels of single-stranded DNA probes specific for
four of the five IE genes were hybridized with nuclear run-on
RNA as described in Materials and Methods. Labeled RNA
was prepared from nuclei treated for various lengths of time
with anisomycin and harvested at 5 h p.i. The analysis
revealed a differential pattern of IE transcription that mir-
rored the differences in mRNA accumulation and protein
synthesis results seen earlier. Maximum transcription of
10
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ICPO occurred in nuclei from cells treated from the time of
infection (0 h) (Fig. 4A). Maximum transcription of ICP22
and ICP27 occurred in nuclei from cells treated with ani-
somycin at 0.5 h p.i. (Fig. 4B). While differences between
the 0- and 0.5-h points for both ICP22 and ICP27 are small,
they are reproducible and display a maximum rate depen-
dent on infected cell protein synthesis. With regard to
ICP22, these results are consistent with protein synthesis
(Fig. 2) and mRNA accumulation (Fig. 3) data. Finally,
maximal ICP4 transcription (Fig. 4A) occurred after a delay
of 1 h before drug addition. ICP8, a DE gene (Fig. 4C), ICP5,
an L or gamma-1 gene (Fig. 4D), and gC, an L or gamma-2
gene (Fig. 4D), displayed a pattern of delayed transcription
consistent with their kinetic class designation and provided
evidence that the run-on analysis faithfully reflected the
regulation seen in vivo (24, 67, 69). These results argue
strongly that the requirement for infected cell protein syn-
thesis for maximum IE gene expression exists at the level of
transcription.
DISCUSSION
The results of many studies describing kinetics and meta-
bolic requirements (27, 29-31, 39), promoter structure (5, 18,
21, 22, 33, 40, 41), and rates of transcription (24, 67, 70) have
supported a unified mechanism for positive regulation of the
IE genes. In the experiments described here, we have
attempted to determine whether any other positive regula-
tory mechanisms underlie the VP16-mediated effects. The
impetus for these studies came from work demonstrating
that the virion transactivator is not required for reactivation
from latency (63) and that ICPO appears to be important for
critical early steps in the replication cycle, when virion DNA
rather than infectious virus initiates infection (6). Our ap-
proach was to amplify the consequences of very early
regulatory events in HSV infection. This was achieved by
varying the length of time for which infected cell protein
synthesis was allowed and observing the consequences on
rates of transcription, accumulation, and expression of cy-
toplasmic mRNA. The results support the conclusion that a
requirement for infected cell protein synthesis exists for
maximal expression of ICP4, ICP22, and ICP27, but not
ICPO, genes. We have no direct evidence for the protein
synthesis requirement for maximal transcription of ICP47.
From the pattern of mRNA accumulation (Fig. 3) and the
fact that ICP22 and ICP47 have identical promoter se-
quences, it is likely that this IE gene has a similar require-
ment for infected cell protein synthesis for maximal expres-
sion. Accumulation of ICP27 mRNA may have an additional
requirement beyond that shared with ICP4, -22, and -47
mRNAs for maximal transcription (compare results in Fig.
3B and 4B). The highest rate of synthesis under our condi-
tions of drug treatment was coincident with that of ICP4 in
the in vitro run-on assay. In an earlier analysis of transcrip-
tion rates in untreated intact infected cells, the time of
maximal synthesis of ICP27 lagged behind that of ICP4 (70).
Though the significance of transcription rates of ICP27
compared with ICP22/47 and ICP4 is unknown, we have
consistently observed delayed maximal expression of these
four IE genes relative to ICPO (data not shown). The ratio of
accumulated ICPO to ICP4 mRNAs in the absence of de
novo protein synthesis was approximately 6:1 (Fig. 3), while
the ratio of ICP4 to ICPO transcription under these same
conditions was approximately 2:1 (Fig. 4). This finding likely
reflects differences in the size of the specific probes used in
the two types of assays. For the Northern blot experiments,
TABLE 1. Comparison of Northern blot hybridization and
nuclear run-on transcription for ICPO and ICP4
Run-on Northern blotProtein transcriptiona hybridizationb
ICPO 1,412/0.658 = 2,145 1.8/4.5 = 0.4
lCP4 1,207/1.5 = 804 0.2/1.8 = 0.11
(2.67)c (3.63)c
a Counts per minute of a 0-h anisomycin run-on RNA sample hybridized per
kilobase of specific probe.
b Relative absorbance of an autoradiographic image of a 0-h anisomycin
steady-state RNA sample per kilobase of specific labeled DNA probe.
Ratio of normalized values for ICPO and ICP4 samples.
ICPO and ICP4 probes were 4.5 and 1.8 kb in size, respec-
tively, while in the run-on transcription assay, the two
probes were 0.66 and 1.5 kb, respectively. Table 1 summa-
rizes the quantitative data from the Northern blot and run-on
transcription assays, presented as units of RNA detected
(either relative amounts or counts per minute hybridized) per
kilobase of probe for both ICPO and ICP4 transcripts. The
ratios of ICPO to ICP4, once normalized for the method of
quantitation, vary from 2.7 to 3.6.
One of the earliest papers describing the cascade regula-
tion of HSV gene expression (29) reported that as the onset
of inhibition of protein synthesis was delayed relative to the
time of infection, the subsequent rates of synthesis of IE
polypeptides ICP4, -0, and -27 declined continuously after
removal of the block. On the basis of this and subsequent
experiments (30) on the effects of canavanine on the pattern
of viral protein synthesis, the authors concluded that one or
more polypeptides of the DE and L classes were required for
the turn-off of the IE class. While our results are consistent
with this conclusion, we have noted differences in the
metabolic requirements for ICP4 and ICP27 synthesis after
removal of a protein synthesis block. Some obvious differ-
ences in the experimental approach include cell type (HEp-2
versus Vero) and the use of cycloheximide rather than
anisomycin. Accumulation of viral mRNA restricted to the
IE class has previously been demonstrated with emetine,
cycloheximide, and anisomycin over a range of 0.6 to 5.5%
residual protein synthesis (39). We routinely achieved 98%
inhibition of protein synthesis with 25 ,uM anisomycin in
Vero cells and could effect complete recovery of protein
synthesis within a 30-min period by washing monolayers in
drug-free medium and preventing further RNA synthesis by
addition of actinomycin D (unpublished data). One possible
explanation for the differences in protein synthesis patterns
after drug reversal is the inclusion of the 30-min recovery
time. Perhaps we were able to indirectly detect differences in
the levels of accumulated functional mRNAs that were not
detectable by labeling immediately after drug reversal, a
time when translational capacity is not fully restored. In any
event, these Northern blot and run-on transcription results,
which should be independent of the previous considerations,
clearly indicate differential effects on transcription and IE
mRNA accumulation as a function of prior protein synthesis.
It is unlikely that our results obtained by using anisomycin
were due to effects of the drug distinct from inhibition of
protein synthesis. First, we observed an inverse relationship
between the accumulation and expression of ICP4, -22, -27,
and -47 mRNAs and the length of drug treatment, arguing
against an mRNA stabilization or superinduction effect (42).
Second, the patterns of transcription, accumulation, and
expression of ICPO and ICP4 mRNA were consistently and
J. VIROL.
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demonstrably different (this work and data not shown),
arguing against some general nonspecific effect of the drug
on mRNA metabolism or expression. Finally, we would
argue that the de novo protein synthesis-dependent change
in IE transcription is not due to alterations in the properties
of the virion-associated transactivator VP16, since its bind-
ing and that of Oct-I to consensus TAATGARAT target sites
can be demonstrated in vitro in the absence of protein
synthesis (55). It remains a formal possibility, however, that
the formation of the DNA-protein complex merely precedes
a protein synthesis-dependent step that results in promoter
activation.
It is tempting to speculate that the requirement for de novo
protein synthesis for maximal expression of ICP4 and per-
haps ICP22/47 and ICP27 is in fact a requirement for ICPO.
The transactivating properties of the ICPO protein on IE
target promoters (21, 22, 48) as well as DE and heterologous
promoters (12, 19, 48, 56) has been well documented. The
ICPO gene product is a nuclear phosphoprotein, and exten-
sive mutagenesis studies and sequence inspection (8, 14, 16,
52, 71) have revealed activation domains as well as potential
sites of protein-protein interaction (15). The present results
clearly indicate that the ICPO gene has requirements for
maximal expression which differ from those of ICP4 and the
other IE genes. This, in turn, suggests that a partially
nonoverlapping set of transcription factor-promoter se-
quence interactions may regulate the ICPO gene and the
other IE genes. While inspection of upstream promoter
sequences of ICP4 and ICPO reveals motifs mediating Spl
and TATA box factor binding, two sequence motifs in the
ICPO promoter are not shared with the ICP4 promoter. First,
there is a near consensus CAAT box (GCCATT) centered at
position -77 relative to the transcription start site. Second,
there are three copies of the sequence YCTTTGGGG, at
positions -213, -151, and -51. In addition, the number and
sequence organization of the TAATGARAT sites in the
ICP4 and ICPO promoters differ. The ICP4 promoter con-
tains two TAATGARAT sites which lack overlapping Oct-1
consensus binding sites (T sites [3]) and which weakly bind
the VP16/Oct-1 complex as measured by a gel mobility
assay. The ICPO promoter contains four sites, consisting of
overlapping octamer and TAATGARAT sequences (O/T
sites [3]), which bind the VP16/Oct-1 complex more
strongly. It remains to be determined whether any of these
differences in consensus factor binding sites mediate the
differential activation of the ICPO promoter. Experiments
are in progress to further substantiate the role of ICPO in the
regulation of IE transcription.
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